Treatment and Prophylaxis of Cardiac Allograft Vasculopathy

Transplantation Proceedings

Volumn 40, Issue 8, 2008, Pages 2609-2610

  Wang, S S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTERY INTIMA PROLIFERATION; ARTICLE; ASIA; B LYMPHOCYTE; CARDIAC ALLOGRAFT VASCULOPATHY; CELL PROLIFERATION; CYTOMEGALOVIRUS; DISEASE COURSE; ENDOTHELIUM INJURY; EXERCISE; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; OBESITY; ORGAN DONOR; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVASCULARIZATION; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; SMOOTH MUSCLE FIBER; VIRUS INFECTION;

B-LYMPHOCYTES; HEART TRANSPLANTATION; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TUNICA INTIMA; VASCULAR DISEASES;

EID: 53149124786     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.08.073     Document Type: Article

References (18)

1. Avery R.K. Cardiac allograft vasculopathy. N Engl J Med 349 (2003) 829
2. Methra M.R., Ventura H.O., Stapleton D.D., et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 14 (1995) 632
3. Frigerio M., Carascia A., Roubina E., et al. Cardiac allograft vasculopathy: differences in de novo and maintenance heart transplant recipients. Transplantation 82 (2006) S5
4. Kobashigawa J.A. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 22 (2003) 711
5. Hsu R.B., Chu S.H., Wang S.S., et al. Low incidence of transplant coronary artery disease in Chinese heart recipients. J Am Coll Cardiol 33 (1999) 1573
6. Wang H.J., Ko W.J., Lee C.M., et al. Delayed occurrence of cardiac allograft vasculopathy in Chinese heart transplant recipients compared with their Western counterparts. Clin Transplant 18 (2004) 21
7. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869
8. Uehara S., Chase C.M., Kitchens W.H., et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 175 (2005) 3424
9. Hsu R.B., Fang C.T., Chang S.C., et al. Infectious complications after heart transplantation in Chinese recipients. Am J Transplant 5 (2005) 2011
10. Wang C.H., Ko W.J., Chou N.K., et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. Transplant Proc 36 (2004) 2384
11. Wang S.S., Chou N.K., Ko W.J., et al. Effect of plasmapheresis for acute humoral rejection after heart transplantation. Transplant Proc 38 (2006) 3692
12. Wu Y.W., Lee C.M., Lee Y.T., et al. Value of circulating adhesion molecules in assessing cardiac allograft vasculopathy. J Heart Lung Transplant 22 (2003) 1284
13. Lee C.M., Wu Y.W., Chou N.K., et al. Intravascular ultrasound evidence of angiographically silent allograft vasculopathy inversely correlates with circulating level of hepatocyte growth factor. J Heart Lung Transplant 25 (2006) 1456
14. Ma H., Calderon T.M., Fallon J.T., et al. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 164 (2002) 79
15. Yamaura K., Ito K., Tsukioka K., et al. Suppression of acute and chronic rejection by hepatocyte growth factor in murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 110 (2004) 1650
16. Segovia J., Gomez-Bueno M., and Alonso-Pullpon L. Treatment of allograft vasculopathy in heart transplantation. Expert Opin Pharmacother 7 (2006) 2369
17. Kaczmarek I., Ertl B., Schmauss D., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung transplant 25 (2006) 550
18. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847